YAROSHEVSKY GLANVILLE MARY 4
4 · ANADYS PHARMACEUTICALS INC · Filed Jan 11, 2006
Insider Transaction Report
Form 4
YAROSHEVSKY GLANVILLE MARY
Senior Director, Human Capital
Transactions
- Sale
Common Stock
2006-01-09$10.20/sh−130$1,326→ 1,196 total - Sale
Common Stock
2006-01-09$10.11/sh−81$819→ 1,115 total - Exercise/Conversion
Stock Option (Right to Buy)
2006-01-09−1,500→ 5,363 totalExercise: $2.95From: 2002-04-17Exp: 2011-06-20→ Common Stock (1,500 underlying) - Sale
Common Stock
2006-01-09$10.15/sh−400$4,060→ 1,926 total - Sale
Common Stock
2006-10-09$10.21/sh−200$2,042→ 1,726 total - Sale
Common Stock
2006-01-09$10.16/sh−200$2,032→ 1,526 total - Exercise/Conversion
Common Stock
2006-01-09$2.95/sh+1,500$4,425→ 1,500 total - Sale
Common Stock
2006-01-09$10.10/sh−600$6,060→ 900 total - Sale
Common Stock
2006-01-09$10.13/sh−500$5,065→ 400 total - Sale
Common Stock
2006-01-09$10.11/sh−300$3,033→ 100 total - Sale
Common Stock
2006-01-09$10.15/sh−100$1,015→ 0 total - Sale
Common Stock
2006-01-09$10.14/sh−570$5,780→ 2,326 total
Footnotes (3)
- [F1]The reported sales were effected pursuant to a trading plan established under Rule 10b5-1 of the Securities and Exchange Act of 1934.
- [F2]Includes 1,448 shares which were acquired pursuant to the Anadys Pharmaceuticals, Inc. 2004 Employee Stock Purchase Plan on November 15, 2004, includes 933 shares which were acquired pursuant to the Anadys Pharmaceuticals, Inc. 2004 Employee Stock Purchase Plan on May 15, 2005, and includes 1,115 shares which were acquired pursuant to the Anadys Pharmaceuticals, Inc. 2004 Employee Stock Purchase Plan on November 15, 2005.
- [F3]The option vested and became exercisable over a period of four years. All shares subject to the option have vested and are exercisable as of the date of this filing.